Onkologie. 2014:8(1):24-26

Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer

Eva Kindlová
Radioterapeutická a onkologická klinika 3. lékařské fakulty Univerzity Karlovy
a Fakultní nemocnice Královské Vinohrady, Praha

Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer. Until recently, treatment options

have been limited to docetaxel, standard first-line chemotherapy. New studies with cabazitaxel, abirateron, enzalutamid, sipuleucel-T

and Ra-223 have shown improvement in survival in CRPC patients. Radium-223 dichloride is alpha-emitting radioisotope that targets

areas of osteoblastic metastasis.

Keywords: castration-resistant prostate cancer, PSA, bone metastasis, Radium-223 dichloride

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kindlová E. Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer. Onkologie. 2014;8(1):24-26.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hafeez S, Parker Ch, RoyalMarsdenHospital, UK, Expert Opin., Investig.Drugs, 2013; 22:3, 379-387, Radium-223 for the treatment of prostate cancer. Go to original source... Go to PubMed...
    2. Parker C, Nilson S, Heindrich D, Helle SI, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl.J Med 2013: 18213-223. Go to original source...
    3. Harrison MR, Wong TZ, Amstrong AJ, George DJ. Radium-223 chloride: a potentional new treatmentn for castration-resistent prostate cancer patiens with metastatic bone disease.Cancer Management and Resaerch 2013: 5: 1-14. Go to original source... Go to PubMed...
    4. Fínek J. Xofigo (radium-223 dichlorid) v léčbě metastatického kastračně resistentního karcinomu prostaty Klin.Onkol. 2013; 226(6).
    5. Kolombo I, Kolombová J, Dvořáček J, Hanuš T. Skeletální postižení v uroonkologii, Galen, 2005.
    6. Prostate cancer: ESMO Consensus Conference Guidelines 2012 A. Horwich, J. Hugosson, T. de Reijke, T. Wiegel, K. Fizazi, V. Kataja, Panel Members.
    7. Heidenreich A (chair), Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F, EAU 2013; Guidelines on Prostate Cancer. Podpořeno z výzkumného projektu PRVUK P 27/2012 Univerzity Karlovy, 3. lékařské fakulty v Praze.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.